3.36
Schlusskurs vom Vortag:
$3.31
Offen:
$3.33
24-Stunden-Volumen:
82,018
Relative Volume:
0.24
Marktkapitalisierung:
$178.70M
Einnahmen:
$230.47M
Nettoeinkommen (Verlust:
$30.28M
KGV:
5.5082
EPS:
0.61
Netto-Cashflow:
$38.86M
1W Leistung:
+5.16%
1M Leistung:
-2.33%
6M Leistung:
+9.09%
1J Leistung:
+4.02%
Puma Biotechnology Inc Stock (PBYI) Company Profile
Firmenname
Puma Biotechnology Inc
Sektor
Branche
Telefon
(424) 248-6500
Adresse
10880 WILSHIRE BLVD., LOS ANGELES, CA
Vergleichen Sie PBYI mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PBYI
Puma Biotechnology Inc
|
3.355 | 178.70M | 230.47M | 30.28M | 38.86M | 0.61 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
444.12 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
528.17 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
319.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
560.62 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
240.84 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2021-09-28 | Hochstufung | Citigroup | Neutral → Buy |
2020-06-25 | Fortgesetzt | BofA/Merrill | Underperform |
2019-10-08 | Herabstufung | Goldman | Neutral → Sell |
2019-05-10 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2019-05-10 | Herabstufung | Citigroup | Buy → Neutral |
2019-01-17 | Eingeleitet | Leerink Partners | Mkt Perform |
2019-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
2018-11-19 | Hochstufung | Goldman | Sell → Neutral |
2018-11-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
2018-11-02 | Herabstufung | JP Morgan | Neutral → Underweight |
2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
2018-09-17 | Eingeleitet | Goldman | Sell |
2018-05-11 | Bestätigt | Stifel | Buy |
2017-11-10 | Bestätigt | Citigroup | Buy |
2017-11-10 | Bestätigt | RBC Capital Mkts | Sector Perform |
2017-10-02 | Bestätigt | Stifel | Buy |
2017-09-11 | Bestätigt | Credit Suisse | Outperform |
2017-07-10 | Fortgesetzt | Leerink Partners | Outperform |
2017-06-06 | Bestätigt | RBC Capital Mkts | Sector Perform |
2017-05-25 | Bestätigt | RBC Capital Mkts | Sector Perform |
2017-03-02 | Bestätigt | RBC Capital Mkts | Sector Perform |
Alle ansehen
Puma Biotechnology Inc Aktie (PBYI) Neueste Nachrichten
Puma Biotechnology Holds Annual Stockholders Meeting 2025 - TipRanks
Should Value Investors Buy Puma Biotechnology (PBYI) Stock? - Yahoo Finance
With 57% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) boasts of strong institutional backing - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Sold by Squarepoint Ops LLC - Defense World
78,653 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Purchased by Mackenzie Financial Corp - Defense World
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 - BioSpace
Puma Biotechnology Awards Key Talent with 18,250 RSUs in Strategic Retention Move - Stock Titan
Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors - sharewise
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Fly 25% But Investors Aren't Buying For Growth - simplywall.st
Is Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Puma Biotechnology Inc (PBYI) Forecast: Revisiting The Past To Gain Insights For The Future - Stocksregister
Puma Biotechnology's (NASDAQ:PBYI) Earnings Are Of Questionable Quality - Yahoo Finance
Puma Biotechnology targets $192M-$198M NERLYNX revenue for 2025 amid strategic efforts - MSN
Puma Biotechnology, Inc. (NASDAQ:PBYI) Shares Bought by Wells Fargo & Company MN - Defense World
Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock - Nasdaq
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates - MSN
Puma Biotechnology First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2025 Earnings Call Transcript - Insider Monkey
Puma Biotech CCO Jeff Ludwig departs, no replacement named By Investing.com - Investing.com Canada
Puma Biotech CCO Jeff Ludwig departs, no replacement named - Investing.com
Puma Biotechnology, Inc. Announces Termination of Jeff J. Ludwig as Chief Commercial Officer - marketscreener.com
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? - Yahoo Finance
Puma Biotechnology Terminates Chief Commercial Officer - TipRanks
Puma Biotechnology Inc (PBYI) Q1 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges By GuruFocus - Investing.com Canada
Puma Biotechnology Reports Positive Q1 2025 Earnings - TipRanks
Puma Biotech Q1 2025 slides: NERLYNX revenue up 7% YoY despite quarterly decline - Investing.com Canada
Puma Biotech: Q1 Earnings Snapshot - The Washington Post
Cautious Hold Rating on Puma Biotechnology Amid Declining Sales and Uncertain Trial Outcomes - TipRanks
Earnings call transcript: Puma Biotech Q1 2025 results miss forecasts By Investing.com - Investing.com UK
Puma Biotechnology Reports First Quarter Financial Results - BioSpace
Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Earnings call transcript: Puma Biotech Q1 2025 results miss forecasts - Investing.com
Check out these key findings about Puma Biotechnology Inc (PBYI) - Sete News
Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients - The Manila Times
Er-Kim Announces Exclusive Distribution Agreement with Puma - GlobeNewswire
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 - Yahoo Finance
Finanzdaten der Puma Biotechnology Inc-Aktie (PBYI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Puma Biotechnology Inc-Aktie (PBYI) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Stuglik Brian M | Director |
Jun 13 '25 |
Sale |
3.39 |
8,100 |
27,459 |
94,958 |
Senderowicz Adrian | Director |
Jun 13 '25 |
Sale |
3.40 |
27,000 |
91,800 |
27,000 |
MOYES JAY M | Director |
Jun 13 '25 |
Sale |
3.40 |
22,000 |
74,800 |
53,322 |
Dorval Allison | Director |
Jun 13 '25 |
Sale |
3.40 |
11,610 |
39,474 |
75,390 |
Cesano Alessandra | Director |
Jun 13 '25 |
Sale |
3.40 |
12,150 |
41,310 |
68,850 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):